Search Results 1901-1910 of 19647 for Hemoglobin

1. Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer - Mayo Clinic

   * hemoglobin ≥ 9g/dL (without use of erythropoietin; without packed RBC transfusion within preceding 2 weeks) * platelet count ≥100,000/?cL * total ...

2. A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) - Mayo Clinic

   Hemoglobin ≥ 90 g/L (9.0 g/dL). Patients may be transfused to meet this criterion. AST, ALT, and ALP ≤ 2.5 x upper limit of normal (ULN); Serum bilirubin ...

3. A Phase 2/3 Study To Investigate The Safety And Efficacy Of Brepocitinib In Adults With Lichen Planopilaris (ALPINE) - Mayo Clinic

   Hemoglobin < 10 g/dL (100 g/L);. Platelet count < 100 × 109 /L (< 100,000/mm3 );. Absolute neutrophil count (ANC) < 1.5 × 109 /L (< 1500/mm3 );. Absolute ...

4. Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). - Mayo Clinic

   Adequate organ and marrow function as defined below: Hemoglobin ≥9.0 g/dL without transfusion 4 weeks prior to the screening and randomization: Absolute ...

5. Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes (REVITALIZE 1) - Mayo Clinic

   Current persistent anemia, defined as hemoglobin \<10g/dL 27. Use of anticoagulation therapy (e.g., warfarin, coumadin, or novel oral anticoagulants \[NOACs ...

6. A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies - Mayo Clinic

   Hemoglobin ≥8.0 g/dL (Grade ≤2) maintained for ≥2 weeks from any prior transfusion. Note: In Part 2 (Cohort Expansion), Grade ≥3 neutropenia ...

7. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and Combined with Chemotherapy or Tislelizumab to Treat Patients with Metastatic Solid Tumors - Mayo Clinic

   hemoglobin ≥ 8.5 g/dL without transfusion in the previous week;; creatinine ≤ 1.5 x upper limit of normal (ULN);; aspartate aminotransferase AST (SGOT) ≤ 3 ...

8. Pirtobrutinib And Venetoclax With MRD Detection For Previously Untreated Chronic Lymphocytic Leukemia - Mayo Clinic

   * Hemoglobin \>= 8 g/dL (obtained =\< 14 days prior to registration) * Activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and ...

9. A Study of TAS-120 in Patients With Metastatic Breast Cancer - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL without transfusion support (that is, excluding measurements within 7 days after transfusion of packed red blood cells or whole blood); ...

10. An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC - Mayo Clinic

    purposes). 8. Patients must have adequate organ function: - Bone marrow reserve ANC ≥1.5 x 109/L Platelets ≥100 x 109/L Hemoglobin ≥9 g/dL - Hepatic ...